Physician profile
Bridgette Smith
NPI 1194477265
$2,888.34
in general payments reported to CMS, 2019-2025
24 companies · $898 in 2025
The $898 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $271 · 2023: $873 · 2024: $847 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,617.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $610.18 | 2022-2025 | |
| Pfizer INC. | $342.65 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $332.38 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $325.35 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $161.18 | 2022-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $143.06 | 2022-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $127.75 | 2022-2024 | Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $120.19 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.37 | 2022-2025 | Xifaxan, Trulance |
| Almatica Pharma LLC | $104.02 | 2022-2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Otsuka America Pharmaceutical, INC. | $75.12 | 2023-2025 | Nuedexta, Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.30 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $70.69 | 2025 | Fanapt |
| Xeris Pharmaceuticals, INC. | $53.91 | 2022-2025 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $36.52 | 2023-2025 | Entyvio, Trintellix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $32.47 | 2024 | Veozah |
| Dexcom, INC. | $28.65 | 2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $25.37 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $25.19 | 2023 | Uzedy |
| Idorsia Pharmaceuticals US INC | $21.74 | 2022 | |
| Axsome Therapeutics, INC. | $20.72 | 2023 | Sunosi |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.14 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.63 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridgette Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.